We use cookies to provide you with the best possible experience. They also allow us to analyze user behavior in order to constantly improve the website for you.
Oops! Something went wrong while submitting the form.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Serialization is not one-size-fits-all. With varying mandates across the U.S., EU, Asia, and the Middle East, companies must navigate a complex web of requirements. Are you prepared for global compliance?
Find out how LSPedia is pushing forward the world of traceability. Our monthly newsletter is your guide to the serialized supply chain – from DSCSA compliance to industry events and technological advances – and beyond.
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Current Issue - January/February 2026
Highlights
Compliance at Risk: Tightening DSCSA enforcement threatened Pioneer Pharmacy's wholesale operations and business continuity.
Enforcement Is Here: As of January 2026, FDA inspections now actively verify DSCSA compliance, with the first Form 483 issued to a dispenser following the end of the stabilization period.
Disconnected PMS, EHR, and inventory systems create redundant scanning, manual entry, and operational inefficiencies.
Pharmacies must obtain a GS1 Company Prefix from GS1 US to generate and manage compliant GLNs.
In this edition: A regulator’s take on DSCSA, LSPedia achieves FedRAMP In-Process designation, pharmacists earn CE credits through hands-on DSCSA training, and more!
In this edition: AI & ML are Revolutionizing Regulatory Affairs, Optimizing Supply Chains with ASNs, LSPedia CEO, Riya Cao Launches Executive Newsletter and more!
DSCSA Enforcement Begins May 27 – 6 Critical Actions to Protect Your Shipments FDA enforcement is around the corner. LSPedia outlines six key actions—like validating EPCIS connections and resolving exceptions—to help manufacturers and repackagers stay compliant and keep shipments moving.
LSPedia’s Daniel MacKinnon met with leading pharma manufacturers in India frustrated by outdated systems and poor support. His latest blog explains why many are making the switch to LSPedia.
Matt Vincent, Director of Sales at LSPedia, breaks down the FDA’s DSCSA exemptions and their importance as the stabilization period ends on November 27, 2024.
LSPedia has introduced a new Waivers, Exceptions, and Exemptions (WEEs) resource page, providing essential answers to pressing questions from those considering requesting a waiver for additional time to achieve DSCSA compliance and how to manage WEEs going forward with trading partners.
In the pharmaceutical industry, maintaining a resilient and sustainable supply chain is paramount for ensuring product integrity, regulatory compliance, and operational efficiency.